OverviewSuggest Edit

Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment.
TypePublic
Founded2012
HQRedwood City, CA, US
Websiteguardanthealth.com
Employee Ratings4
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)622(+38%)
Job Openings256
Revenue (FY, 2020)$286.7 M(+34%)
Share Price (May 2021)$135.4(-11%)
Cybersecurity ratingBMore

Key People/Management at Guardant Health

Helmy Eltoukhy

Helmy Eltoukhy

Chief Executive Officer and Director
AmirAli Talasaz

AmirAli Talasaz

President and Chief Operating Officer, Chairman of the Board
Ian Clark

Ian Clark

Lead Independent Director
Bahija Jallal

Bahija Jallal

Director
Vijaya Gadde

Vijaya Gadde

Director
Samir Kaul

Samir Kaul

Director
Show more

Guardant Health Office Locations

Guardant Health has an office in Redwood City
Redwood City, CA, US (HQ)
505 Penobscot Dr
Show all (1)

Guardant Health Financials and Metrics

Guardant Health Revenue

Guardant Health's revenue was reported to be $286.73 m in FY, 2020
USD

Revenue (Q1, 2021)

78.7m

Net income (Q1, 2021)

(107.4m)

EBIT (Q1, 2021)

(107.9m)

Market capitalization (7-May-2021)

13.7b

Closing stock price (7-May-2021)

135.4

Cash (31-Mar-2021)

869.4m

EV

14.2b
Guardant Health's current market capitalization is $13.7 b.
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Revenue

25.2m49.8m214.4m286.7m

Revenue growth, %

97%

Cost of goods sold

22.1m31.6m

Gross profit

3.1m18.2m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

8.5m10.2m11.1m16.7m19.4m21.7m90.6m36.7m54.0m60.8m67.5m66.3m74.6m78.7m

Cost of goods sold

6.4m7.4m9.1m9.3m10.0m

Gross profit

2.1m2.8m2.0m7.4m9.4m

Gross profit Margin, %

25%27%18%45%49%
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Cash

33.6m72.3m143.2m833.0m

Accounts Receivable

33.5m12.8m48.0m53.3m

Prepaid Expenses

1.6m1.5m11.4m17.5m

Inventories

2.8m7.3m15.2m22.7m
Quarterly
USDQ2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

110.8m114.0m140.5m153.8m174.7m147.2m152.2m164.7m142.9m869.4m

Accounts Receivable

10.6m14.6m35.7m29.0m40.4m39.7m48.0m41.0m36.3m48.0m

Prepaid Expenses

3.0m4.0m5.2m6.2m4.1m5.7m14.1m11.1m9.9m15.7m

Inventories

6.7m7.1m9.1m10.3m14.2m14.8m25.1m20.4m27.7m28.9m
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(46.1m)(83.2m)(67.9m)(246.3m)

Depreciation and Amortization

3.7m5.2m11.4m16.1m

Inventories

(351.0k)(4.5m)(6.0m)(7.5m)

Accounts Payable

2.1m1.3m4.3m(7.9m)
Quarterly
USDQ2, 2017Q2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(39.6m)(35.5m)(59.0m)(84.3m)(21.4m)(32.7m)(45.7m)(31.8m)(81.6m)(153.2m)(107.4m)

Depreciation and Amortization

2.5m3.0m5.0m7.1m2.4m5.0m8.0m3.3m7.1m11.5m5.0m

Inventories

(1.1m)559.0k212.0k(1.8m)(1.1m)(5.0m)(5.6m)(10.0m)(5.2m)(12.5m)(6.2m)

Accounts Payable

680.0k823.0k3.3m5.0m(2.6m)3.4m426.0k9.5m(2.5m)846.0k12.0m
USDFY, 2016

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.5 x
Show all financial metrics

Guardant Health Operating Metrics

Guardant Health's Users was reported to be 5 k in Q2, 2018. Guardant Health's Enterprise Customers was reported to be 40 in Q2, 2018.
Q2, 2018

Enterprise Customers

40

Users

5 k
Show all operating metrics

Guardant Health Acquisitions / Subsidiaries

Company NameDateDeal Size
Bellwether BioApril 01, 2019

Guardant Health Revenue Breakdown

Embed Graph

Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other

Guardant Health Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Guardant Health Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Guardant Health Online and Social Media Presence

Embed Graph

Guardant Health Company Culture

  • Overall Culture

    B

    80/100

  • CEO Rating

    A

    82/100

  • Compensation

    B-

    74/100

Learn more on Comparably

Guardant Health News and Updates

Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa

MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. This accolade is a testament to the success of the company's flagship liquid biopsy,...

Liquid Biopsy Market Growth Rate of 23.80% by 2026 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by QIAGEN, MDxHealth, CareDx, Inc., Immucor, Inc., Menarini Silicon Biosystems, Guardant Health, Myriad Genetics

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Data Bridge Market Research has added a new report titled Global Liquid Biopsy Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Global Liqu…

Première biopsie liquide à recevoir l'approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.

SINGAPOUR, 8 août 2020 /PRNewswire/ -- La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides....

Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development

Represents a large-scale liquid biopsy dataset of advanced cancer patients Represents a large-scale liquid biopsy dataset of advanced cancer patients

Guardant Health Announces Pricing of Upsized Public Offering

REDWOOD CITY, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the pri…

Guardant Health AMEA wins this year's Growth Excellence Leadership Award by Frost & Sullivan

SINGAPORE, Nov. 22, 2019 /PRNewswire/ -- Guardant Health AMEA has won Frost & Sullivan's Growth Excellence Leadership Award under the Best Practices Category for 2019 Asia-Pacific Liquid Biopsy for Precision Oncology. "We are delighted to receive this prestigious award from Frost &...
Show more

Guardant Health Blogs

Guardant Health Reports Third Quarter 2020 Financial Results

Guardant Health Reports Third Quarter 2020 Financial Results Content Import Thu, 11/05/2020 - 16:06 Guardant Health Reports Third Quarter 2020 Financial Results November 5, 2020 This release is a backfill from a News Wire Earnings Q…

Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Oct. 16, 2020-- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020 . Company management will be webcasting a corresponding conference call beginning

Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Oct. 15, 2020-- Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the

Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder

Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder pamleonardo Wed, 10/07/2020 - 09:06 Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder October 7, 2020 This release is a backf…

Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder

Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder pamleonardo Tue, 10/06/2020 - 16:54 Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder October 6, 2020 This release is a backfill …

Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy

Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy carolyn.forest… Mon, 10/05/2020 - 16:05 Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy October…
Show more

Guardant Health Frequently Asked Questions

  • When was Guardant Health founded?

    Guardant Health was founded in 2012.

  • Who are Guardant Health key executives?

    Guardant Health's key executives are Helmy Eltoukhy, AmirAli Talasaz and Ian Clark.

  • How many employees does Guardant Health have?

    Guardant Health has 622 employees.

  • What is Guardant Health revenue?

    Latest Guardant Health annual revenue is $286.7 m.

  • What is Guardant Health revenue per employee?

    Latest Guardant Health revenue per employee is $461 k.

  • Who are Guardant Health competitors?

    Competitors of Guardant Health include Caris Life Sciences, Castle Biosciences and Biodesix.

  • Where is Guardant Health headquarters?

    Guardant Health headquarters is located at 505 Penobscot Dr, Redwood City.

  • Where are Guardant Health offices?

    Guardant Health has an office in Redwood City.

  • How many offices does Guardant Health have?

    Guardant Health has 1 office.